Haemonetics Corporation (HAE) Earnings History
Annual and quarterly earnings data from 1992 to 2025
Loading earnings history...
HAE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HAE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 57.2% | 16.3% | 12.3% |
| 2024 | 54.4% | 12.6% | 9.0% |
| 2023 | 53.3% | 13.4% | 9.9% |
| 2022 | 53.4% | 8.1% | 4.4% |
| 2021 | 49.2% | 10.3% | 9.1% |
Download Data
Export HAE earnings history in CSV or JSON format
Free sign-in required to download data
Haemonetics Corporation (HAE) Earnings Overview
As of May 6, 2026, Haemonetics Corporation (HAE) reported trailing twelve-month net income of $175M, reflecting +44.5% year-over-year growth. The company earned $3.73 per diluted share over the past four quarters, with a net profit margin of 12.3%.
Looking at the long-term picture, HAE's 5-year EPS compound annual growth rate (CAGR) stands at +17.5%, indicating exceptional earnings growth. The company achieved its highest annual net income of $168M in fiscal 2025, representing a new all-time high.
Haemonetics Corporation maintains positive profitability with a gross margin of 57.2%, operating margin of 16.3%, and net margin of 12.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including TFX (-$906M net income, -45.4% margin), HOLX ($544M net income, 13.8% margin), ITGR ($142M net income, 5.6% margin), HAE has outperformed on profitability metrics. Compare HAE vs TFX →
HAE Earnings vs Peers
Earnings metrics vs comparable public companies
HAE Historical Earnings Data (1992–2025)
34 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $168M | +42.6% | $222M | $3.31 | 12.3% | 16.3% |
| 2024 | $118M | +1.9% | $165M | $2.29 | 9.0% | 12.6% |
| 2023 | $115M | +166.1% | $156M | $2.24 | 9.9% | 13.4% |
| 2022 | $43M | -45.4% | $81M | $0.84 | 4.4% | 8.1% |
| 2021 | $79M | +3.8% | $90M | $1.55 | 9.1% | 10.3% |
| 2020 | $77M | +39.1% | $103M | $1.48 | 7.7% | 10.5% |
| 2019 | $55M | +20.7% | $84M | $1.04 | 5.7% | 8.6% |
| 2018 | $46M | +273.5% | $56M | $0.85 | 5.0% | 6.2% |
| 2017 | -$26M | +52.8% | -$19M | $-0.51 | -3.0% | -2.2% |
| 2016 | -$56M | -429.2% | -$44M | $-1.09 | -6.1% | -4.8% |
See HAE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HAE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HAE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
Is HAE growing earnings?
HAE EPS is $3.73, with earnings growth accelerating to +44.5%. This exceeds the 5-year CAGR of +17.5%. TTM net income reached $175M.
What are HAE's profit margins?
Haemonetics Corporation net margin is +12.3%, with operating margin at +16.3%. Margins sit within typical range for the sector.
How consistent are HAE's earnings?
HAE earnings data spans 1992-2025. The accelerating earnings trend is +44.5% YoY. Historical data enables comparison across business cycles.